Abstract

BackgroundThe Human Immune Deficiency Virus (HIV) can manifest neurologically in both adults and children. Early invasion of the central nervous system by the virus, affecting the developing brain, is believed to result in the most common primary HIV-related neurological complication, HIV Encephalopathy (HIVE). In countries such as South Africa where many children have not been initiated on antiretroviral treatment early, HIVE remains a significant clinical problem.MethodsChildren were selected from a clinic for children with neurologic complications of HIV, located at the Red Cross War Memorial Children’s Hospital, South Africa 2008–2012. Eligible subjects fulfilled the following inclusion criteria: aged 6 months-13 years; positive diagnosis of HIV infection, vertically infected and HIVE as defined by CDC criteria. Each participant was prospectively assessed by a Pediatric Neurologist using a standardized proforma which collated relevant details of background, clinical and immunological status.Results The median age of the 87 children was 64 months (interquartile range 27–95 months). All except one child were on antiretroviral treatment, 45% had commenced treatment <12 months of age. Delayed early motor milestones were reported in 80% and delayed early speech in 75% of children in whom we had the information. Twenty percent had a history of one or more seizures and 41% had a history of behavior problems. Forty-eight percent had microcephaly and 63% a spastic diplegia. CD4 percentages followed a normal distribution with mean of 30.3% (SD 8.69). Viral loads were undetectable (<log 1.6) in 70% of the children. Brain imaging was performed on 56% with 71% of those imaged demonstrating at least one abnormality, most commonly white matter volume loss or signal abnormality. ConclusionsAmongst the cohort of children referred to this clinic, the diagnosis of HIVE was unrecognized in the general medical services, even in its most severe form. Developmental delay and school failure were major presenting problems. Co-morbidities are a frequent finding and should be sought actively in order to optimize management and promote best possible outcomes for this vulnerable group of children.

Highlights

  • Introduction ofantiretroviral therapy (ART) is associated with prolonged survival rates of children suffering from Human Immune Deficiency Virus (HIV) by promoting a broad spectrum of general and specific health measures including normal growth and development, improved immunity, reduced risk of and vulnerability to infections [36,37]

  • According to the World Health Organization, approximately 3.4 million children worldwide are suffering from Human immunodeficiency Virus (HIV) or Acquired immune deficiency syndrome (AIDS) with >90% of them residing in sub-Saharan Africa [1,2,3]

  • Those women with CD4 count ≤ 200 cells/μL were commenced on antiretroviral therapy (ART), while those with a CD4 count >200 cells/μL were commenced on zidovudine prophylaxis at 34–36 weeks gestation, and during labour administered a single dose of NVP

Read more

Summary

Introduction

Introduction ofART is associated with prolonged survival rates of children suffering from HIV by promoting a broad spectrum of general and specific health measures including normal growth and development, improved immunity, reduced risk of and vulnerability to infections [36,37]. Invasion of the central nervous system by the virus, affecting the developing brain, is believed to result in the most common primary HIV-related neurological complication, HIV Encephalopathy (HIVE). In countries such as South Africa where many children have not been initiated on antiretroviral treatment early, HIVE remains a significant clinical problem. In mid2004 an intensified PMTCT programme was introduced based on the CD4 count of all HIV-infected pregnant women Those women with CD4 count ≤ 200 cells/μL were commenced on antiretroviral therapy (ART), while those with a CD4 count >200 cells/μL were commenced on zidovudine prophylaxis at 34–36 weeks gestation, and during labour administered a single dose of NVP. Between 2004 and 2013 this programme underwent several revisions including progressive liberalization of the criteria used to initiate ART in pregnant women, introduction of 6 week infant testing (previously 14 weeks), introduction of extended NVP prophylaxis for all HIVexposed infants, promotion of breastfeeding, and the withdrawal of free-formula milk in 2012 [5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call